Heron Therapeutics Inc (HRTX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

4242 CAMPUS POINT COURT, SUITE 200 SAN DIEGO, CA 92121

A P Pharma Inc. develops ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The company's main focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer.

Data as of 2020-11-22
Market Cap1.674 Billion Shares Outstanding90.855 Million Avg 30-day Volume749.633 Thousand
P/E Ratio-7.5 Dividend Yield EPS-2.47
Price/Sales16.23 Price cash flow ratio Price free cash flow ratio-10.0
Book Value3.05 Price to Tangible Book6.04 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.224355
BETA1.56427 52-week High/Low26.81 / 9.6 Stddev0.139169
View SEC Filings from HRTX instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 4 4 0.0% 1 (0.07%) 1 (0.06%) 0.0%
Funds Holding: 177 188 -5.85% 56 (3.68%) 54 (3.5%) 3.7%
13F shares: 89.433 Million 87.132 Million 2.64% 35.938 Million 31.251 Million 15.0%
% Ownership 98.4346 95.902 2.64% 39.5556 34.397 15.0%
New Positions: 20 35 -42.86% 9 10 -10.0%
Increased Positions 61 68 -10.29% 19 22 -13.64%
Closed Positions 28 38 -26.32% 7 17 -58.82%
Reduced Positions 63 53 18.87% 20 14 42.86%
Total Calls 55.284 Thousand 325.161 Thousand -83.0% 22.5 Thousand 99.8 Thousand -77.45%
Total Puts 73.51 Thousand 413.311 Thousand -82.21% 31.7 Thousand 139 Thousand -77.19%
PUT/CALL Ratio 1.33 1.27 4.72% 1.41 1.39 1.44%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding HRTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding HRTX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

QUART BARRY D CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
89,226 2020-10-13 3

DAVIS STEPHEN

  • Director
0 2020-10-13 3

MANHARD KIMBERLY EVP, DRUG DEVELOPMENT

  • Officer
  • Director
0 2020-10-13 3

POYHONEN JOHN PRESIDENT & CCO

  • Officer
0 2020-10-13 2

CHRISTIAN WAAGE

  • Director
0 2020-10-13 3

PERAZA LISA VP, CHIEF ACCOUNTING OFFICER

  • Officer
0 2020-10-13 2

SZEKERES DAVID LESLIE EVP, CHIEF OPERATING OFFICER

  • Officer
3,571 2020-10-13 1

TANG KEVIN C

  • Director
5,038,491 2019-12-31 2

JOHNSON CRAIG A

  • Director
0 2019-12-19 1

HOFFMAN ROBERT CFO & SVP, FINANCE

  • Officer
0 2019-12-19 1

ROSEN ROBERT PRESIDENT

  • Officer
  • Director
0 2018-12-15 0

TANG KEVIN C

TANG CAPITAL MANAGEMENT LLC

TANG CAPITAL PARTNERS LP

  • Director
  • 10% Owner
5,851,503 2018-09-12 0

DRAZBA BRIAN G. VP, FINANCE & CFO

  • Officer
3,798 2016-04-29 0

MARSHALL PAUL SVP, TECHNICAL OPERATIONS

  • Officer
2,200 2016-03-21 0

CLENDENINN NEIL JAMES SVP & CHIEF MEDICAL OFFICER

  • Officer
0 2015-10-12 0

SPCH, LLC

MIDLER ANDREW R

  • EXITING 10% HOLDEREXITING 10% HOLDER
No longer subject to file 2014-12-31 0

SAVITR CAPITAL, LLC

  • EXITING 10% HOLDER
No longer subject to file 2014-12-31 0

GELDER MARK S. MD SVP & CHIEF MEDICAL OFFICER

  • Officer
0 2014-12-12 0

WHELAN JOHN CFO

  • Officer
254,088 2013-07-18 0

ADAM MICHAEL A CHIEF OPERATING OFFICER

  • Officer
0 2013-02-08 0

SPCH, LLC

  • 10% Owner
0 2013-01-01 0

GODDARD PAUL

  • Director
  • CHAIRMAN
0 2012-05-29 0

TURNBULL GREG

  • Director
0 2012-05-29 0

BARR JOHN VICE PRESIDENT OF R&D

  • Officer
0 2011-07-08 0

BAKER BROS. CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
No longer subject to file 2011-07-01 0

BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
No longer subject to file 2011-07-01 0

14159 CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
No longer subject to file 2011-07-01 0

BAKER BIOTECH CAPITAL (GP), LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
No longer subject to file 2011-07-01 0

BAKER / TISCH CAPITAL (GP), LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
No longer subject to file 2011-07-01 0

PERCEPTIVE ADVISORS LLC

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

  • 10% Owner
26,666,667 2011-07-01 0

ZERBE ROBERT L MD

  • Director
202,072 2010-05-20 0

ROSENBLATT TOBY

  • Director
210,234 2010-05-20 0

PRENTKI RONALD J PRESIDENT & CEO

  • Officer
  • Director
0 2010-02-17 0

TAYLOR ARTHUR T

  • Director
15,000 2008-05-28 0

RIEPENHAUSEN PETER

  • Director
71,900 2008-02-28 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

MANHARD KIMBERLY - Director - Officer EVP, DRUG DEVELOPMENT

2020-10-15 16:25:38 -0400 2020-10-13 A 120,000 a 120,000 direct

CHRISTIAN WAAGE - Director

2020-10-15 16:21:10 -0400 2020-10-13 A 437 a 437 direct

QUART BARRY D - Director - Officer CHIEF EXECUTIVE OFFICER

2020-10-15 16:23:41 -0400 2020-10-13 A 58,333 a 58,333 direct

POYHONEN JOHN - Officer PRESIDENT & CCO

2020-10-15 16:24:39 -0400 2020-10-13 A 170,000 a 170,000 direct

PERAZA LISA - Officer VP, CHIEF ACCOUNTING OFFICER

2020-10-15 16:35:53 -0400 2020-10-13 A 8,833 a 8,833 direct

QUART BARRY D - Director - Officer CHIEF EXECUTIVE OFFICER

2020-10-15 16:23:41 -0400 2020-10-13 A 350,000 a 350,000 direct

MANHARD KIMBERLY - Director - Officer EVP, DRUG DEVELOPMENT

2020-10-15 16:25:38 -0400 2020-10-13 A 20,000 a 20,000 direct

DAVIS STEPHEN - Director

2020-10-15 16:20:17 -0400 2020-10-13 A 765 a 765 direct

PERAZA LISA - Officer VP, CHIEF ACCOUNTING OFFICER

2020-10-15 16:35:53 -0400 2020-10-13 A 103,000 a 103,000 direct

POYHONEN JOHN - Officer PRESIDENT & CCO

2020-10-15 16:24:39 -0400 2020-10-13 A 20,000 a 20,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments